Riskpilot← Back to searchSign inGet full accessDermadent Sweclinic AB
ABActiveOrg 5590510599Humblegatan 34Dental practice care activities · NACE 8623Est. 20165-9 employees
Revenue 2024
SEK 1,7M
+245% vs 2023
EBITDA margin
7.3%
+140% vs 2023
Equity ratio
37.0%
Financial strength
Net profit 2024
SEK 248K
-41% vs 2023
| Revenue | SEK 1,7M | +245% |
| EBITDA | SEK 127K | +140% |
| Net profit | SEK 248K | -41% |
| Total assets | SEK 2,1M | +63% |
| Equity | SEK 786K | +23% |
| Employees | — | — |
Legal name
Dermadent Sweclinic AB
Org number
5590510599
Legal form
Aktiebolag
NACE code
8623 · Dental practice care activities
Founded
12 februari 2016
Share capital
SEK 50 000
Employees
5-9
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas ensam av Abdallatif, Mohammed Khalil Ali
Company purpose
Bolaget ska bedriva tand- och skönhetsvård.
Address
Humblegatan 34
Phone
+468304051
Email
info@dermadent.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 247 | 499 | 1 724 |
| Staff expenses | — | — | — | −611 | −828 |
| EBITDA | −14 | −1 | 226 | −314 | 127 |
| Depreciation & amort. | −0 | −0 | — | −5 | −90 |
| EBIT | −14 | −1 | 226 | −320 | 36 |
| Net financials | — | — | 0 | 849 | 283 |
| Profit before tax | −14 | −1 | 226 | 529 | 320 |
| Tax | −0 | −0 | −44 | −109 | −72 |
| Net profit | −14 | −1 | 183 | 420 | 248 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 71 | 71 | 274 | 1 300 | 2 124 |
| Equity | 36 | 36 | 218 | 638 | 786 |
| Long-term debt | 0 | 0 | — | — | 800 |
| Short-term debt | 35 | 35 | 56 | 662 | 538 |
| Total debt | 35 | 35 | 56 | 662 | 1 338 |
EBITDA margin
7.3%
This company
15.8%
Market median
-54% vs market
20202024
Equity ratio
37.0%
This company
38.2%
Market median
+3% vs market
20202024
Return on equity
31.5%
This company
18.4%
Market median
+71% vs market
20202024
Net profit margin
14.4%
This company
8.1%
Market median
+78% vs market
20202024
Asset turnover
0.81×
This company
1.12×
Market median
+28% vs market
20202024
Debt / equity
1.70×
This company
0.62×
Market median
-174% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
MK Chief Executive Officer | Chief Executive Officer | 2020 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2020 | |
| Former (1) | ||
| Deputy Board Member | 2020 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Dermadent Sweclinic AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Mohammed Khalil Ali Abdallatif | Chief Executive Officer | 0 companies |
| Imad Abdallatif | Deputy Board Member | 0 companies |
| Nasser Naje Lazem | Deputy Board Member | 0 companies |